Roche, WO42758, Intrinsic, Ph 1/1b, OL, mCRC, Inavolisib + Cetuximab or Inavolisib + Bevacizumab

What is the Purpose of this Study?

Inavo + Cetux Treatment Arm Primary Efficacy Objectives: To evaluate the efficacy of Inavo + Cetux in PIK3CA-mutated CRC with no detected RAS (KRAS, NRAS) or BRAFV600E mutations Secondary Efficacy Objectives: To evaluate the efficacy of Inavo + Cetux in PIK3CA-mutated CRC with no detected RAS (KRAS, NRAS) or BRAFV600E mutations Inavo + Bev Arm Primary Efficacy Objectives: To evaluate the efficacy of Inavo + Bev in PIK3CA-mutated, RAS (KRAS, NRAS)-mutated CRC Secondary Efficacy Objectives: To evaluate the efficacy of Inavo + Bev in PIK3CA-mutated, RAS (KRAS, NRAS)-mutated CRC

Eligibility

* Signed cohort-specific Informed Consent Form
* Age \>= 18 years at time of signing Informed Consent Form
* Biomarker eligibility as determined at a College of American Pathologists/clinical laboratory improvement amendments (CAP/CLIA)-certified or equivalently accredited diagnostic laboratory using a validated test
* Eastern Cooperative Oncology Group (ECOG) Performance Status of \<= 1

Inclusion Criteria

* Signed cohort-specific Informed Consent Form
* Age \>= 18 years at time of signing Informed Consent Form
* Biomarker eligibility as determined at a College of American Pathologists/clinical laboratory improvement amendments (CAP/CLIA)-certified or equivalently accredited diagnostic laboratory using a validated test
* Eastern Cooperative Oncology Group (ECOG) Performance Status of \<= 1
* Life expectancy \>= 3 months, as determined by the investigator
* Histologically confirmed adenocarcinoma originating from the colon or rectum
* Metastatic disease
* Prior therapies for metastatic disease
* Ability to comply with the study protocol, in the investigators judgment
* Measurable disease (at least one target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
* Baseline tumor tissue samples will be collected from all patients for exploratory biomarker research
* Adequate hematologic and organ function within 14 days prior to initiation of study treatment
* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures
* For men: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm

Exclusion Criteria

* Current participation or enrollment in another interventional clinical trial. Patients who are participating in the follow-up period of an interventional clinical trial are eligible for the study.
* Any systemic anti-cancer treatment within 2 weeks or 5 half-lives (whichever is shorter) prior to start of study treatment
* Treatment with investigational therapy within 28 days prior to initiation of study treatment
* Pregnant or breastfeeding, or intending to become pregnant during the study
* History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study or confounds the ability to interpret data from the study
* Severe infection within 4 weeks prior to initiation of study treatment or any active infection that, in the opinion of the investigator, could impact patient safety
* Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of study treatment
* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
* Uncontrolled tumor-related pain
* Uncontrolled or symptomatic hypercalcemia
* Clinically significant and active liver disease
* Negative HIV test at screening, with the following exception: Patients with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy for at least 4 weeks, have a CD4 count greater than or equal to 200/uL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months.
* Symptomatic, untreated, or actively progressing CNS metastases
* History of leptomeningeal disease or carcinomatous meningitis
* History of malignancy other than CRC within 2 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
* Any other disease, unresolved toxicity from prior therapy, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
* Requirement for treatment with any medicinal product that contraindicates the use of any of the study treatments, may interfere with the planned treatment, affects patient compliance, or puts the patient at higher risk for treatment-related complications

Show less

Where can I participate?

CS Cancer at Beverly Hills
CS Cancer at Cedars-Sinai Medical Center
Hunt Cancer Institute, an Affiliate of Cedars-Sinai Cancer

More about this Clinical Trial

What is the full name of this clinical trial?

WO42758: A Phase I/Ib Global, Multicenter, Open-Label Umbrella Study Evaluating The Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer

Study Details

Disease Type/Condition

Colon

Principal Investigator

Gong, Jun

Co-Investigators

Andrew Hendifar, Andrew Horodner, Arsen Osipov, David Chan, David Hoffman, Hugo Hool, Jeremy Lorber, Kevin Scher, Swati Sikaria, Syed Jilani, Thomas Lowe, Vanessa Dickey

Age Group

Adult

Phase

IRB Number

STUDY00001565

ClinicalTrials.gov ID

NCT04929223

Key Eligibility

ClinicalTrials.gov

How do I learn more about this study?

clinicaltrials@cshs.org